Jefferies Group’s Harvard Bioscience HBIO Stock Holding History

Jefferies Group’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,805	Closed	-$36K	–	2823
2019 Q2	$36K	Buy	+1,805	New	+$52.9K	﹤0.01%	2395

Other funds holding HBIO

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Jefferies Group's HBIO Position: Q3 2019 in Review

Jefferies Group sold out of Harvard Bioscience (HBIO) in Q3 2019, closing a stake of 1,805 shares — an estimated $36K sold.

Jefferies Group first reported a position in HBIO in Q2 2019 and held it in 1 quarter. The position peaked at $36K in Q2 2019. 71 funds tracked by Wall St. Rank hold HBIO as of Q3 2019.

Jefferies Group reported no remaining Harvard Bioscience position as of Q3 2019 after selling out during the quarter.
Jefferies Group sold 1,805 Harvard Bioscience shares in Q3 2019, an estimated $36K.
Jefferies Group first reported a position in Harvard Bioscience in Q2 2019 and held it in 1 quarter.
Jefferies Group's Harvard Bioscience position peaked at $36K in Q2 2019.
71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.